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S U M M A R Y
Objective: To estimate the number of people living in Thailand with chronic hepatitis B (CHB), a major
cause of liver cirrhosis and cancer, in view of the implementation of programs to prevent CHB
complications.
Methods: Using PubMed/Medline and ScienceDirect, all studies reporting hepatitis B surface antigen
(HBsAg) seroprevalence estimates conducted in Thailand and published between 1975 and 2015 were
reviewed systematically. Pooled prevalence estimates and their 95% conﬁdence intervals (CIs) were
calculated, and potential sources of heterogeneity investigated.
Results: A high heterogeneity was observed between prevalence estimates. There was a signiﬁcant
decrease in the 150 estimates of HBsAg prevalence with more recent decades of birth (p < 0.001), even
before the implementation of the national universal immunization program in 1992. When restricted to
the general population, the pooled prevalence estimate was 5.1% (95% CI 4.3–6.0%), which would
translate to an estimated number of individuals with CHB living in Thailand in 2015 as high as three
million.
Conclusions: The high burden of CHB in Asian countries is a major challenge for the incorporation of
national programs to prevent CHB complications within health care systems.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chronic infection with the hepatitis B virus (HBV) affects an
estimated 240 million persons worldwide.1 It is believed to cause
liver cirrhosis and hepatocellular carcinoma (HCC) in at least 25%
of affected people, resulting in 780 000 deaths annually,2 most of
them in low- and middle-income countries.3 In 2012, the World
Health Organization (WHO) re-emphasized the need to estimate
the burden of viral hepatitis and improve the assessment of their
global and regional economic impacts.4 Nearly 75% of people
chronically infected with HBV worldwide are from the Southeast
Asia and Western Paciﬁc regions,5 where chronic hepatitis B (CHB)* Corresponding author. Tel.: +66 (0)5381 9125 to 29; fax: +66 (0)5381 9130.
E-mail address: gonzague.jourdain@ird.fr (G. Jourdain).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).infection is 30 times more prevalent than HIV and represents a
major public health issue.
In 1992, the Department of Disease Control of the Ministry of
Health incorporated HBV universal immunization (starting with a
birth dose) in the Expanded Program on Immunization (EPI). Since
2011, the EPI has been managed by the National Health Security
Ofﬁce as a vertical program, with the Government Pharmaceutical
Organization in charge of the distribution of all vaccines to public
hospitals. The vaccines are administered free of charge. The
coverage rate increased from 15% in 1992 to 95% in 2000 and has
reached levels of 99% since 2013. However, immune globulin is not
always available for infants born to hepatitis B surface antigen
(HBsAg)-positive mothers.6 As observed in all settings where such
programs have been implemented, this has resulted in a dramatic
reduction in the prevalence; for example, 0.3% in Thai children
born before 2015.7 However, the prevalence is still high in peopleociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
C. Leroi et al. / International Journal of Infectious Diseases 51 (2016) 36–43 37born before 1992, and the increasing incidence of associated
complications in relation to the increase in life expectancy has
become a major concern.8 Currently, only pregnant women are
screened routinely for HBsAg during antenatal care and only a
small proportion of those with CHB who meet the criteria for
treatment do receive antiviral treatment. To plan for national
programs, information on CHB prevalence by birth year is needed.
A systematic review and meta-analysis was conducted to
synthesize CHB prevalence data in the general population in
Thailand, overall and by birth year.
2. Methods
2.1. Literature search strategy
A systematic review of the peer-reviewed literature for HBsAg
prevalence data was conducted following the 2009 PRISMA
statement guidelines (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses)9 by searching PubMed/MEDLINE and
ScienceDirect (Elsevier) with a combination of medical subject
heading (MeSH) terms and free text words used in research
equations with ‘OR’ and ‘AND’ logical operators (Supplementary
Material, Checklist S1). All relevant articles were reviewed and
their reference lists hand-searched to identify additional studies.
The references cited by review articles were also examined.
Additionally, sources in the Thai language were investigated. All
duplicate entries were removed and all citations managed with the
bibliographic management tool Zotero. The literature was last
searched on January 19, 2016.
2.2. Eligibility criteria
All articles meeting the following criteria were screened and
then assessed for eligibility: peer reviewed publications published
from 1975 to December 2015, reporting HBsAg seroprevalence
estimates, specifying the period over which the study was
conducted, and providing a description of the population involved
and the number of people tested for HBsAg. Review articles,
conference abstracts, editorials, and case reports were excluded.
Reports of analytical studies (cross-sectional studies, prospective
or retrospective) and clinical trials were included, with no
restriction on age or type of population.
2.3. Data extraction and study outcomes
After study selection, the following data were extracted by two
independent reviewers (CL and PA) using a data extraction form
(Supplementary Material, File S1): study identiﬁcation (ﬁrst
author, publication year, journal of publication), period over which
the study was conducted, population, design, direct or indirect
information on participant years of birth, numerator and
denominator for estimated HBsAg estimates, and sex distribution.
Data were entered into a table and imported into Stata version 13.1
(StataCorp, College Station, TX, USA) for analysis. Each of the two
experts independently checked and compared the extracted data.
Discrepancies or disagreements were resolved by consensus; a
third expert was consulted if needed (GJ).
The primary study outcome was the proportion of subjects with
HBsAg considered as affected by chronic infection, as in high
prevalence countries the vast majority of transmissions occur
perinatally or during early childhood and are followed by chronic
infection.
The populations were categorized into general population, new
blood donors and unspeciﬁed blood donors (new and regular blood
donors pooled when unspeciﬁed), health care workers, people
living with HIV, people who use drugs, and men who have sex withmen (MSM). Medical students were considered as health care
workers and pregnant women as part of the general population.
Participant years of birth were calculated using the mean or
median age and the period over which the study was conducted.
The year of birth was imputed for one study on Thai workers going
abroad based on national statistics on age at migration of such
workers; in another study on blood donors, the year of birth was
based on the average age known for this population. When a study
was conducted over several years, the mean year of the study was
used. Whenever possible, estimates were extracted by age group or
by study period. Birth year was categorized into ﬁve classes:
1960, 1961–1970, 1971–1980, 1981–1991, and 1992 (in
Thailand, individuals born in or after 1992 could have been
immunized through the national program).
2.4. Quality assessment
The quality of the studies was assessed using a score varying
from 0 to 4, with 1 point awarded in each case if the number of
participants screened was 1000 or more, selection of the
participants screened was random, information on age and
sex was available, and the recruitment period was provided. In
the meta-regression analysis, the effects of each criterion and
that of the total quality score on the prevalence estimates were
assessed.
2.5. Data synthesis and analysis
The estimated prevalence of CHB infection was calculated as the
number of HBsAg-positive subjects divided by the total number of
subjects screened.
Overall and sub-group-speciﬁc prevalence estimates were
computed using a random-effects meta-analysis (metaprop pro-
cedure, Stata)10 to account for uncertainty in pooled estimates due
to between-study heterogeneity (e.g., patient characteristics,
location of study, study design). The 95% conﬁdence intervals
(CI) for the individual studies included were estimated by exact or
Clopper–Pearson conﬁdence limits for a binomial proportion.11
The Freeman–Tukey double arcsine transformation was performed
to compute the weighted pooled estimate.12 The inter-study
heterogeneity and the heterogeneity across studies were assessed
using the I2 measure.13
2.6. Test for publication bias
The presence of publication bias was assessed graphically by
funnel plot and formally by its direct statistical analogue, the Egger
adjusted rank correlation test,14 using the metabias program in
Stata.15
2.7. Additional analyses
Potential effects of demographics (birth year, proportion of
men, type of population, and age) and methodological character-
istics (study period, sample size, and quality score) on HBsAg
prevalence estimates were explored with random-effects meta-
regression using the metareg procedure in Stata.16 The overall p-
value was estimated for each variable using a Monte Carlo
permutation test to address multiple testing. Only covariates
identiﬁed as possibly associated (p < 0.25) in a ﬁrst-step univari-
able analysis were included in the multivariable model, and a
backward selection process was then used (p < 0.05). In addition,
the probability plot of standardized shrunken residuals was
estimated to check the quality of the ﬁnal model.
The absolute prevalence of CHB by age in 2015 in the general
population was computed using the prevalence rates and the age
C. Leroi et al. / International Journal of Infectious Diseases 51 (2016) 36–4338group distribution in Thailand in 2015, as published by the United
Nations (UN) Population Division.17
3. Results
3.1. General scope
Of 341 references identiﬁed through database searching and
27 additional records identiﬁed through other sources, 288 articles
were excluded after screening titles and abstracts. Of the
remaining 80 articles, 54 eligible articles were included in the
systematic review and meta-analysis (Figure 1). The character-
istics of the studies are summarized in the Supplementary
Material, Table S1.
In terms of population, 26 studies were conducted in the
general population (including one in pregnant women),7,18–42 six
in new blood donors,43–48 four in unspeciﬁed blood donors,49–52
seven in people living with HIV,53–59 seven in health care
workers,60–66 two in people who used drugs,67,68 one in MSM,69
and one in both the general population and people living with
HIV.70 In terms of design, 34 studies were cross-sectional,7,18–
37,43,44,49,50,53,54,60–65,70 13 were retrospective analyses of medical
records,38–41,45–48,51,52,55,56,66 four were prospective cohort stud-
ies,42,57,58,69 and three were clinical trials.59,67,68 In terms of sex
distribution, 47 studies (87%) were conducted in both sexes, ﬁve in
females, and two in males. In terms of quality, 25 of the 54 studies
(46%) had a total quality score 3. Most studies reported the age
and sex distribution of the population (85%), as well as the period
of recruitment (90%), but only 22% were based on a randomly
selected population sample and only 37% had a sample of at least
1000 individuals (Supplementary Material, Table S1).
The median year of publication was 2006 (interquartile range
(IQR) 1999 to 2012). There was no evidence of a publication bias, as
shown by the funnel plots (Supplementary Material, Figure S1)
(Egger test, p = 0.33).Figure 1. Flow diagram of the systema3.2. Overall and subgroup prevalence estimates
In the 54 studies, there were 150 age-, year-, and/or sex-speciﬁc
prevalence estimates of HBsAg status from a total of 989 574 per-
sons in Thailand. Figure 2 presents each study prevalence estimate
and the overall pooled prevalence estimates for each population
obtained through meta-analysis in a forest plot. The pooled
prevalence estimates ranged from 0.6% (95% CI 0.0–3.1%) to 14.7%
(95% CI 7.3–27.4%), with high heterogeneity between studies
(I2 = 99.3%).
Subgroup pooled prevalence estimates with no adjustment are
shown in Figure 3. The meta-analysis showed that the prevalence
differed signiﬁcantly across populations (p = 0.002). When re-
stricted to general population studies, the estimate was 5.1% (95%
CI 4.3–6.0%). It was higher in MSM (8.1%, 95% CI 6.6–9.7%) and
people living with HIV (8.1%, 95% CI 6.4–9.9%) compared with the
general population. The lowest prevalence was found in unspeci-
ﬁed blood donors (2.8%, 95% CI 1.7–4.0%), but the prevalence in
new blood donors was close to the general population prevalence
(5.8%, 95% CI 5.4–6.3%). In health care workers, it was 5.2% (95% CI
3.5–7.2%). The prevalence was lower in children (<15 years)
compared to those in the older groups (p = 0.02). Signiﬁcant
differences were noted depending on the study design (p = 0.001):
the estimates were as high as 10.4% in cohort studies and 7.5% in
clinical trials, but 5.6% in cross-sectional studies and 3.6% in
retrospective studies. The prevalence was lower in studies with a
quality score 3 (4.0%, 95% CI 3.5–4.7% vs. 6.2%, 95% CI 5.8–6.6%;
p < 0.001).
3.3. Prevalence of HBsAg according to birth year
The 150 groups had a median birth year of 1965 (IQR 1952–
1983). The meta-analysis showed that the pooled prevalence
decreased signiﬁcantly in groups born during the more recent
years (p = 0.002): from 6.3% (95% CI 5.7–6.8%) in those born beforetic review, Thailand, 1975–2015.
Figure 2. Forest plot of the prevalence estimates for the different populations, Thailand, 1975–2015. Meta-analyses with random-effects models. Abbreviations: CI,
conﬁdence interval; ES, estimated prevalence.
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1.3% (95% CI 0.3–2.7%) after 1992 (when the national immuniza-
tion program started) (Figure 4). A signiﬁcant decline in HBsAg
prevalence in the more recent birth years was observed in the
general population (p < 0.001), as well as in all other groups
(Figure 4), including people living with HIV who consistently carry
the greatest HBV burden across all birth periods.3.4. Factors of heterogeneity
The type of population (p = 0.002), age (p = 0.018), birth year
(p = 0.002), study design (p = 0.001), availability of information on
age and sex (p < 0.001), and quality score 3 (p < 0.001) were
associated with the prevalence estimate. Adjusting for the type of
population and study design, the prevalence tended to decrease in
Figure 3. Pooled estimated hepatitis B surface antigen prevalence in Thailand, 1975–2015, estimated by meta-analysis, according to population, age, birth year, sample size,
study design, and quality score. p-Values obtained by permutation in the univariable meta-regression. Abbreviations: CI, conﬁdence interval; EPI, Expanded Program on
Immunization.
Figure 4. Estimated hepatitis B surface antigen prevalence according to birth year in six populations in Thailand, 1975–2015. Abbreviations: GP, general population; HCW,
health care workers; NBD, new blood donors; PLHIV, people living with HIV; PUD, people who use drugs; UBD, unspeciﬁed blood donors.
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Figure 5. Estimated hepatitis B surface antigen prevalence and extrapolation of the number of people living with chronic hepatitis B in the general population in Thailand
according to age in 2015, based on meta-analysis estimates and UN Population Division estimates.17 Abbreviations: HBsAg, hepatitis B surface antigen.
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born before 1961, and the decrease became signiﬁcant for the
groups born during the next decades. In contrast, the multivariable
analysis showed that age, quality criteria, and quality score were
not signiﬁcantly associated with the prevalence estimate. Detailed
results are available in the Supplementary Material, Table S2. The
adjustment of the model was satisfactory, as shown by a low I2, the
percentage of residual variation due to heterogeneity (0.0%), and
R2, the explained proportion of between-study variance (73.4%).
The assumption of normal random-effects was supported by the
probability plot of standardized shrunken residuals: the largest
residual was >2 (Supplementary Material, Figure S2).
3.5. Prevalence according to birth year in the general population
When restricted to the general population group, the preva-
lence estimates ranged from 5.9% to 6.6% in groups born before
1980, then decreased to 3.3% in groups born between 1981 and
1991, and to 1.1% after 1992 (Figure 5). The extrapolation to the
entire population led to an estimated total of 2 931 144 individuals
(95% CI 2 146 079–3 732 527) living with HBsAg in Thailand in
2015 based on the age structure of the Thailand population
provided by the UN17 (Figure 5 and Supplementary Material,
Table S3). The calculation assumed no deaths among individuals
who participated in the studies, and made use of the prevalence
estimate of 0.30% (95% CI 0.17–0.62) provided by a recent survey in
individuals born after 2005 (aged 0–9 years in 2015).7
4. Discussion
According to this systematic review, approximately three
million people in Thailand in 2015 would be HBsAg carriers, with
signiﬁcant differences across age groups. The prevalence estimates
started to decrease in individuals born before 1992, the date on
which the national HBV immunization program was implemented,
but there was a much more pronounced decrease in individuals
born later. The pre-universal immunization decrease may be
related to modiﬁcations of life styles and the increasing use of
disposable devices for all invasive procedures.
In terms of planning for hepatitis B care, estimates of prevalence
by birth year are much more relevant because the risk of CHB
complications is age-dependent, as is the need for treatment to
prevent such complications. It was found that more than 60% of CHB
cases, i.e. more than 1.8 million individuals, were people older than
45 years in 2015. Screening, evaluation, and treatment to prevent
complications are needed for a huge number of individuals.The 2013 WHO prevalence estimates were 6.4% for Thailand
(i.e., about 4.3 million individuals), 4.1% for Cambodia, 3.4% for
Myanmar, 8.7% for Laos, and 10.8% for Vietnam.71 Several factors
may have contributed to differences in estimates, as well as actual
differences in prevalence: a smaller number of available studies
estimating HBsAg prevalence in some neighboring countries and
methodological differences in terms of the estimates, and the
older age of the population in Thailand and time at which
disposable devices became available for use for invasive
procedures in terms of the actual differences. However, one
would expect smaller differences and prevalence estimates closer
to those from a recent study of migrants from neighboring
countries to Thailand.72
The main limitation of this review is the heterogeneity between
the studies. Indeed, studies were conducted in various geographi-
cal areas, using various methods, and targeting different popula-
tions. However, the stratiﬁcation on several characteristics for the
overall estimate minimized the effect of this heterogeneity.
Conversely, the availability of studies on speciﬁc segments of
the population, e.g. drug users, those with HIV, and blood donors,
provides a more detailed account of the situation. Another
limitation is that the birth year in several studies was estimated
using indirect information. Finally, the mortality rate was not
accounted for when calculating the number of cases in 2015; thus
the estimate will be an overestimation in older populations, as the
infection itself is associated with an increased risk of death
compared with the general population.
In conclusion, a very effective program for universal immuni-
zation was implemented in Thailand more than two decades ago.
However, a large number of individuals infected with HBV were
born earlier. Interventions targeted at the older population have
the potential to prevent signiﬁcant morbidity and mortality. A
national program would have to face various challenges, in
particular the large numbers of individuals to be reached, tested,
evaluated, and treated. Estimates similar to that presented for
Thailand in this report could contribute to the preparation of
national programs in other countries.
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